Industry Pipeline

March 2011
Ocular Surgery News;3/25/2011, Vol. 29 Issue 6, p60
Academic Journal
The article focuses on premarket approvals of the U.S. Food and Drug Administration (FDA) including one for MA09-hRPE cell orphan drug status given to Advanced Cell Technology, one for the Zymaxid topical anti-infective flouroquinolone from Allergan, and one for Sun Pharma's market application.


Related Articles

  • Industry Pipeline.  // Ocular Surgery News;4/25/2013, Vol. 31 Issue 8, p46 

    This section offers news briefs in ophthalmology, including recent drug approvals, clearances, and CE mark certification.

  • The missing link: What technologies are lacking for US premium surgeons. Jackson, Mitchell A. // Ocular Surgery News;4/10/2014, Vol. 32 Issue 7, p36 

    The author comments on the apparent gap between the U.S. regulatory approval process of surgical and pharmaceutical products and that of the rest of the world. Topics covered include the need for the U.S. regulatory process to revise its approach, the focus of regulatory process on safety, and...

  • Ophthalmic Business. INDUSTRY NEWS IN BRIEF.  // Ocular Surgery News;9/25/2010, Vol. 28 Issue 18, p35 

    This section offers news briefs related to the ophthalmic equipment and ophthalmic drugs industries. A cooperative marketing agreement has been signed by TearLab Corp. and AMO Canada regarding their dry eye care products. SynergEyes has received approval from the U.S. Food and Drug...

  • Industry Pipeline.  // Ocular Surgery News;11/25/2011, Vol. 29 Issue 22, p41 

    This section offers news briefs related to the ophthalmic business in the U.S. in November 2011 including the Premarket Notification 510(k) application submitted by Freedom Meditech Inc. for its ClearPath DS-120 Lens Fluorescence Biomicroscope, the CE mark approval received by the KS-SP...

  • Industry Pipeline.  // Ocular Surgery News;5/25/2014, Vol. 32 Issue 10, p30 

    This section offers news briefs on ocular surgery as of May 2014. It announces the U.S. Food and Drug Administration's (FDA) approval of the application from Hi-Tech Pharmacal for once-daily bromfenac ophthalmic solution 0.09 percent. Also reported are the 510(k) clearance received by Bausch +...

  • Industry Pipeline.  // Ocular Surgery News;3/25/2013, Vol. 31 Issue 6, p50 

    This section offers news briefs on ophthalmology. Second Sight Medical Products has received the U.S. Food and Drug Administration's (FDA) approval for its Argus II retinal prosthesis system to treat patients with retinitis pigmentosa. Bausch + Lomb has received the FDA's 510(k) clearance for...

  • Dexamethasone/tobramycin.  // Reactions Weekly;7/1/2006, Issue 1108, p8 

    The article presents a case report of intraocular lens opacification which developed in a patient following ophthalmic administration. The patient has cataracts and had undergone lens implantation. After his surgery, the man received ophthalmic administration in the form of an ointment...

  • Industry Pipeline.  // Ocular Surgery News;1/25/2015, Vol. 33 Issue 2, p36 

    The article offers news brief related to approvals in ophthalmology industry as of January 25, 2015. The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to several pharmaceutical companies including Abbott Laboratories Inc., CenterVue and Rayner Intraocular Lenses Ltd....

  • FDA panel recommends approval of riboflavin/UVA cross-linking system. Hasson, Matt // Ocular Surgery News;4/10/2015, Vol. 33 Issue 7, p46 

    The article reports that a joint panel of the U.S. Food and Drug Administration's (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee and Ophthalmic Devices Panel has recommended the approval of Avedro's combined riboflavin ophthalmic solutions and ultraviolet light irradiation for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics